Tags

Type your tag names separated by a space and hit enter

Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers.
Acta Endocrinol Suppl (Copenh). 1987; 286:45-53.AE

Abstract

Ten diabetic teenagers were admitted into our hospital for two nights, separated by one week. In a double-blind cross-over randomized study they received either 50 micrograms of the new long-acting somatostatin analogue Sandostatin sc or placebo. All patients were between 12 and 16 years of age, C-peptide negative with a duration of diabetes of at least four years. They had either conventional therapy or insulin pump therapy. Insulin doses and diets were kept unchanged. Blood samples were taken half hourly from 17.00 h until 09.30 h the next morning from an indwelling venous catheter. Hormonal and metabolic profiles on the two nights were evaluated by means of a distribution free time sequential co-movement analysis and by the paired Wilcoxon's signed rank test. After Sandostatin was given at 22.00 h, GH levels were significantly suppressed during 4 h. During that period blood glucose was slightly but significantly lower than after placebo. The free-insulin profiles from both nights were very comparable. Co-movement analysis showed a significant correlation between glucose and free insulin variations with a 30-min backward shift of the glucose curve. However, after Sandostatin administration this relation was lost in the period between 22.00 and 07.00 h, indicating a different effect of insulin on glucose levels during the nights Sandostatin was given. Early morning glucose rises were associated with free insulin levels below 20 mU/l. This association was not altered during the Sandostatin nights. Glucagon was not suppressed by Sandostatin except at 120 min after injection, and remained unchanged during the rest of the observation period.(ABSTRACT TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Aarsen RS
Department of Paediatrics, University Hospitals, Erasmus University, Rotterdam, The Netherlands.
Bruining GJ
No affiliation info available
Grose WF
No affiliation info available
van Strik R
No affiliation info available
Lamberts SW
No affiliation info available
Harris AG
No affiliation info available

MeSH

3-Hydroxybutyric AcidAdolescentBlood GlucoseCircadian RhythmClinical Trials as TopicDiabetes Mellitus, Type 1Diabetic KetoacidosisDouble-Blind MethodFemaleGlycated HemoglobinGrowth HormoneHumansHydroxybutyratesInsulinInsulin-Like Growth Factor IMaleOctreotidePubertyRandom AllocationSomatostatin

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2892337

Citation

Aarsen, R S., et al. "Long-acting Somatostatin Analogue (Sandostatin) Reduces Late Night Insulinopenic Ketogenesis in Diabetic Teenagers." Acta Endocrinologica. Supplementum, vol. 286, 1987, pp. 45-53.
Aarsen RS, Bruining GJ, Grose WF, et al. Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers. Acta Endocrinol Suppl (Copenh). 1987;286:45-53.
Aarsen, R. S., Bruining, G. J., Grose, W. F., van Strik, R., Lamberts, S. W., & Harris, A. G. (1987). Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers. Acta Endocrinologica. Supplementum, 286, 45-53.
Aarsen RS, et al. Long-acting Somatostatin Analogue (Sandostatin) Reduces Late Night Insulinopenic Ketogenesis in Diabetic Teenagers. Acta Endocrinol Suppl (Copenh). 1987;286:45-53. PubMed PMID: 2892337.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers. AU - Aarsen,R S, AU - Bruining,G J, AU - Grose,W F, AU - van Strik,R, AU - Lamberts,S W, AU - Harris,A G, PY - 1987/1/1/pubmed PY - 1987/1/1/medline PY - 1987/1/1/entrez SP - 45 EP - 53 JF - Acta endocrinologica. Supplementum JO - Acta Endocrinol Suppl (Copenh) VL - 286 N2 - Ten diabetic teenagers were admitted into our hospital for two nights, separated by one week. In a double-blind cross-over randomized study they received either 50 micrograms of the new long-acting somatostatin analogue Sandostatin sc or placebo. All patients were between 12 and 16 years of age, C-peptide negative with a duration of diabetes of at least four years. They had either conventional therapy or insulin pump therapy. Insulin doses and diets were kept unchanged. Blood samples were taken half hourly from 17.00 h until 09.30 h the next morning from an indwelling venous catheter. Hormonal and metabolic profiles on the two nights were evaluated by means of a distribution free time sequential co-movement analysis and by the paired Wilcoxon's signed rank test. After Sandostatin was given at 22.00 h, GH levels were significantly suppressed during 4 h. During that period blood glucose was slightly but significantly lower than after placebo. The free-insulin profiles from both nights were very comparable. Co-movement analysis showed a significant correlation between glucose and free insulin variations with a 30-min backward shift of the glucose curve. However, after Sandostatin administration this relation was lost in the period between 22.00 and 07.00 h, indicating a different effect of insulin on glucose levels during the nights Sandostatin was given. Early morning glucose rises were associated with free insulin levels below 20 mU/l. This association was not altered during the Sandostatin nights. Glucagon was not suppressed by Sandostatin except at 120 min after injection, and remained unchanged during the rest of the observation period.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0300-9750 UR - https://www.unboundmedicine.com/medline/citation/2892337/Long_acting_somatostatin_analogue__Sandostatin__reduces_late_night_insulinopenic_ketogenesis_in_diabetic_teenagers_ DB - PRIME DP - Unbound Medicine ER -